GLAND · NSE
Gland Pharma Limited
₹2,961.9
+1.86% (+₹54.1)
Prev. close
₹2,907.8
Volume
4,92,452
Delivery %
64.9%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Upgraded Gland Pharma to 'buy' from 'hold' on August 11, setting a target of ₹3,350 per share, which implies a 17.9% ups…” | Jefferies AnalysisJefferies | Gland Pharma | PENDING |
Fundamentals
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neurological and central nervous system; blood related, ophthalmics and otologicals, cardiac, gastro-intestinal, and hormonal products; pain, neuromuscular blocking agents, and analgesics; respiratory and pulmonology; and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier preparation, and technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Srinivas Sadu
Headquarters
Hyderabad
Employees
4,332
Website
glandpharma.comExchange
View on NSE ↗Key stats
Market cap
₹48,874.56 Cr
P/E ratio (TTM)
43.3
Dividend yield
0.69%
EPS (TTM)
₹68.33
Beta (1Y · daily vs NIFTY 50)
0.56
Beta (5Y · monthly vs NIFTY 50)
0.29
Shares float
8.94 Cr
EPS · quarter ended Jun 2026
₹19.22
Upcoming earnings
03 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,462.88 Cr | ₹4,400.71 Cr | ₹3,624.60 Cr | ₹5,664.72 Cr | ₹5,616.50 Cr | ₹6,430.65 Cr | |
| EBITDA | ₹1,437.00 Cr | ₹1,734.09 Cr | ₹1,208.77 Cr | ₹1,503.31 Cr | ₹1,482.53 Cr | ₹1,921.53 Cr |
| ₹996.96 Cr | ₹1,211.66 Cr | ₹781.04 Cr | ₹772.46 Cr | ₹698.53 Cr | ₹1,027.32 Cr | |
| Diluted EPS | ₹62.99 | ₹73.64 | ₹47.43 | ₹46.89 | ₹42.4 | ₹62.28 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6,496.00 Cr | ₹7,834.00 Cr | ₹8,778.00 Cr | ₹10,611.00 Cr | ₹11,173.00 Cr | ₹12,449.00 Cr | |
| — | — | ₹4.45 Cr | ₹372.17 Cr | ₹313.73 Cr | ₹283.59 Cr | |
| Stockholders' equity | ₹5,903.00 Cr | ₹7,157.00 Cr | ₹7,958.00 Cr | ₹8,723.00 Cr | ₹9,150.00 Cr | ₹10,357.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹605.00 Cr | ₹791.00 Cr | ₹364.00 Cr | ₹997.00 Cr | ₹915.00 Cr | ₹1,031.00 Cr | |
| Investing cash flow | ₹-1,524.00 Cr | ₹-1,002.62 Cr | ₹1,208.19 Cr | ₹-1,756.91 Cr | ₹1,704.74 Cr | ₹137.73 Cr |
| ₹1,238.00 Cr | ₹35.00 Cr | ₹15.00 Cr | ₹-799.00 Cr | ₹-433.00 Cr | ₹-417.00 Cr | |
| Capital expenditure | ₹-229.00 Cr | ₹-522.00 Cr | ₹-223.00 Cr | ₹-398.00 Cr | ₹-394.00 Cr | ₹-494.00 Cr |
| End cash position | ₹492.46 Cr | ₹318.82 Cr | ₹1,908.90 Cr | ₹357.09 Cr | ₹2,556.21 Cr | ₹3,359.11 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22 | Sep 22–Mar 24(7Q) | Jun 24–Mar 26(8Q) | Jun 26 |
|---|---|---|---|---|---|---|
| Promoter | 58.02% | 58.00% | 57.87% | 57.86% | 51.83% | 51.77% |
| Public | 41.97% | 42.00% | 42.13% | 42.14% | 48.17% | 48.23% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Gland Pharma Limited | ₹46,641.97 Cr | ₹2,907.8 | 41.4 | 4.50 | 9.9% | 0.03 | +14.7% | +46.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
30 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.